Rep. Lisa C. McClain Purchases Shares of Kenvue Inc. (NYSE:KVUE)

Representative Lisa C. McClain (R-Michigan) recently bought shares of Kenvue Inc. (NYSE:KVUE). In a filing disclosed on November 21st, the Representative disclosed that they had bought between $1,001 and $15,000 in Kenvue stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Kenvue Stock Performance

NYSE KVUE traded up $0.19 during trading on Thursday, reaching $17.22. The company’s stock had a trading volume of 46,262,502 shares, compared to its average volume of 54,833,996. The firm has a 50 day moving average price of $16.10 and a 200 day moving average price of $19.65. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17. The firm has a market capitalization of $32.98 billion, a price-to-earnings ratio of 22.95 and a beta of 0.71. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The firm’s quarterly revenue was down 3.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were issued a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. Kenvue’s payout ratio is currently 110.67%.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on KVUE. UBS Group dropped their price objective on Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, October 8th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $15.00 price target (down previously from $26.00) on shares of Kenvue in a report on Wednesday, October 29th. Rothschild Redb raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 26th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a report on Tuesday, October 14th. Finally, The Goldman Sachs Group lowered their price target on Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a report on Thursday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Kenvue has a consensus rating of “Hold” and an average target price of $20.23.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KVUE. Renaissance Capital LLC grew its holdings in shares of Kenvue by 8.3% in the second quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock valued at $13,169,000 after acquiring an additional 48,267 shares in the last quarter. Farther Finance Advisors LLC boosted its position in Kenvue by 80.7% in the second quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock worth $758,000 after purchasing an additional 16,164 shares during the last quarter. Arlington Partners LLC bought a new position in Kenvue in the 2nd quarter valued at $2,110,000. Cornell Pochily Investment Advisors Inc. increased its position in shares of Kenvue by 144.6% during the 2nd quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock valued at $694,000 after purchasing an additional 19,609 shares during the last quarter. Finally, IFP Advisors Inc increased its position in shares of Kenvue by 25.3% during the 1st quarter. IFP Advisors Inc now owns 15,278 shares of the company’s stock valued at $369,000 after purchasing an additional 3,081 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.